2013-03-02 15:51:52 - New Pharmaceuticals research report from GlobalData is now available from Fast Market Research
Alzheimer's disease is the most common cause of dementia in people age 60 years and older and accounts for approximately 75% of the total dementia cases worldwide (Qui et al., 2009). The global prevalence of dementia is estimated to be 3.9% in people age 60 years and older, with an overall Alzheimer's disease prevalence of 9.7% in the US, 4.4% in Europe, and3.4%in developing countries (Kalaria et al., 2008; Lobo et al., 2000; Plassman et al., 2007). An explosive increase in the number of prevalent cases of Alzheimer's disease in all nine markets is expected during the forecast period. GlobalData epidemiologists forecast that prevalent cases of Alzheimer's disease In the nine major markets (the US, France, Germany, Italy, Spain, the
UK, Japan, China, and India) are expected to increase from 12.53 million cases in 2012 to 16.72 million cases in 2022 with an annual growth rate (AGR) of 3.35%. The global burden of the disease is expected to increase due to rapidly aging populations in different parts of the world. Currently, there is no cure for Alzheimer's disease (Mayo Clinic, 2013). Due to the progressive nature of Alzheimer's disease, along with the aging world population, there will be a significant demand for care of persons affected with the disease.
Full Report Details at
- www.fastmr.com/prod/544236_epicast_report_alzheimers_disease_epi ..
* The Alzheimer's disease EpiCast Report provides an overview of the risk factors and comorbidities associated with Alzheimer's disease, as well as global trends in prevalence in the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan) in addition to emerging markets-China and India).
* It also includes a 10-year epidemiological forecast of prevalent cases of Alzheimer's segmented by sex and age (segmented by five-year age groups, beginning at age 60 years and ending at =90 years).
Reasons to buy
* Develop business strategies by understanding the trends shaping and driving the global Alzheimer's disease market.
* Quantify patient populations in the global Alzheimer's disease market to improve product development, pricing, and launch plans.
* Organize sales and marketing efforts by identifying gender and age groups that present the best opportunities for Alzheimer's therapeutics in each of the markets covered.
Report Table of Contents:
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
3.1 Risk Factors and Comorbidities
3.1.1 Family history of Alzheimer's disease increases risk by 7.5 times
3.1.2 APOE ε4 allele triples the risk of Alzheimer's disease
3.1.3 Cardiovascular risk factors increase the risk of Alzheimer's disease by twofold
3.1.4 Incidence and prevalence of Alzheimer's disease double every five years after age 65
3.1.5 Diabetes doubles the risk of Alzheimer's in men, but only marginally increases the risk in women
3.1.6 Women are 1.5 times more likely to develop Alzheimer's disease than men
3.1.7 Mild Cognitive Impairment (MCI) increases the risk of Alzheimer's disease, but may be part of the causal pathway
3.1.8 Depression triples risk of Alzheimer's disease and is the most common comorbidity
3.1.9 Up to 70% of Alzheimer's disease patients also suffer from anxiety
3.1.10 Psychosis and agitation are common comorbidities among Alzheimer's patients
3.2 Global Trends
3.2.1 United States
3.3 Forecast Methodology
3.3.1 Sources Used
3.3.2 Forecast Assumptions and Methods
3.3.3 Sources Not Used
3.4 Epidemiology Forecast (2012-2022)
3.4.1 Prevalent Cases of Alzheimer's Disease
3.4.2 Age-Specific Prevalent Cases of Alzheimer's Disease
3.4.3 Sex-Specific Prevalent Cases of Alzheimer's Disease
3.4.4 Age-Standardized Prevalence of Alzheimer's Disease
3.5.1 Conclusions Regarding Epidemiological Trends
3.5.2 Limitations of the Analysis
3.5.3 Strengths of the Analysis
4.2 About the Authors
4.2.3 Global Director of Epidemiology and Clinical Trials Analysis
4.2.4 Global Head of Healthcare
4.3 About GlobalData
4.4 About EpiCast
4.5 Contact Us
List of Tables
1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Alzheimer's Disease
Table 2: DSM III-R Criteria for the Diagnosis of Dementia
Table 3: NINCDS-ADRDA Criteria for the Diagnosis of Alzheimer's Disease
Table 4: Sources of Epidemiological Data Used for the Forecast
Table 5: All Markets, Prevalent Cases of Alzheimer's Disease, Ages ≥60 Years, Men and Women, N, 2012-2022
Table 6: All Markets, Prevalent Cases of Alzheimer's Disease, by Age, Men and Women, N (Row %), 2012
Table 7: All Markets, Prevalent Cases of Alzheimer's Disease, by Sex, Age ≥ 60 Years, N (Row %), 2012
List of Figures
1.2 List of Figures
Figure 1: All Markets, Prevalent Cases (N) of Alzheimer's Disease, Ages ≥60 Years, Men and Women, 2012-2022
Figure 2: All Markets, Prevalent Cases of Alzheimer's Disease, by Age, Men and Women, N, 2012
Figure 3: All Markets, Prevalent Cases of Alzheimer's Disease, by Sex, Age ≥60 Years, N, 2012
Figure 4: All Markets, Age-Standardized Prevalence of Alzheimer's Disease, Age ≥60 Years, Men and Women, %, 2012
GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.